Search Results for "valsartan"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for valsartan. Results 31 to 33 of 33 total matches.

Apoaequorin (Prevagen) to Improve Memory

   
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021  (Issue 1636)
. Accessed October 14, 2021. ACE inhibitors valsartan statins sacubitril rivaroxaban Plavix peripheral artery ...
A synthetic form of the protein apoaequorin is the active ingredient in the over-the-counter dietary supplement Prevagen (Quincy Bioscience), which is heavily marketed to improve memory.
Med Lett Drugs Ther. 2021 Nov 1;63(1636):175-6 |  Show IntroductionHide Introduction

Drugs for Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 27, 2024  (Issue 1703)
Valsartan – generic Diovan (Novartis) 40, 80, 160, 320 mg tabs 80-320 mg once/day 13.40 277.30 Direct ...
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8   doi:10.58347/tml.2024.1703a |  Show IntroductionHide Introduction

In Brief: Expanded Heart Failure Indication for Dapagliflozin (Farxiga)

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
-angiotensin system inhibitor, sacubutril/ valsartan, beta blocker, mineralocorticoid receptor antagonist ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga – AstraZeneca) was approved by the FDA in 2020 to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF). The indication has now been expanded to include a reduction in the risk of urgent HF visits and use in adults with any left ventricular ejection fraction (LVEF).
Med Lett Drugs Ther. 2023 Jun 26;65(1679):101-2   doi:10.58347/tml.2023.1679c |  Show IntroductionHide Introduction